Snapshot from Aug 02, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Chinese drugmakers face talent shortage
Business talent shortage

Chinese drugmakers face talent shortage

Analysis based on 7 articles · First reported Jul 15, 2026 · Last updated Jul 16, 2026

Sentiment
-10
Attention
3
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The talent shortage may slow Chinese drugmakers' global expansion and increase reliance on partners, potentially affecting their competitiveness. However, the long-term growth trajectory remains intact as companies invest in training and recruitment.

Pharmaceuticals Biotechnology
Event Summary

Leading Chinese drugmakers such as Jiangsu Hengrui and Biopharmaceutical are struggling to recruit internationally experienced staff needed to develop and commercialize medicines overseas. The shortage reflects China's rapid rise as a hub for clinical trials outpacing workforce development. China-headquartered sponsors conducted 88% of trials exclusively in China in 2025, compared to 5% in the United States. Industry executives and experts highlight the acute shortage of talent with global development, regulatory, and cross-cultural expertise. Companies are stepping up internal training and recruitment, but face high costs and competition from multinationals. The talent gap is expected to slow but not derail global expansion plans.

Key Actions
70 Jiangsu Hengrui struggling to recruit
50 Shanghai Henlius Biotech established
40 Sun Piaoyang stated
40 Yu Xuefeng stated
30 Iconiq Capital surveyed
20 Song Yao commented
20 Catherine Gregor stated
20 Richard Pazdur commented
20 Japan — Pharmaceuticals and Medical Devices Agency stated
20 Nihar Parikh commented
20 James Nyssen commented
Entities Involved
cnt
China
Rapid rise as clinical trial hub faces talent bottleneck, potentially slowing global pharmaceutical expansion.
Importance 100.0 Sentiment -10.0
stock
Jiangsu Hengrui
Struggling to recruit internationally experienced staff for global clinical trials and commercialization, which may slow overseas expansion.
Importance 90.0 Sentiment -10.0
per
Sun Piaoyang
Chairman of Hengrui, stated the company faces talent shortages and is stepping up training and recruitment.
Importance 50.0 Sentiment 0.0
per
Yu Xuefeng
CEO of CanSino, noted scarcity of qualified specialists for overseas clinical trials and regulatory submissions.
Importance 50.0 Sentiment 0.0
cnt
United States
US regulators declined some China-tested drugs and called for multi-regional trials, increasing pressure on Chinese drugmakers.
Importance 40.0 Sentiment 0.0
stock
IQVIA
Provided data on clinical trial concentration in China versus the US, highlighting the challenge.
Importance 30.0 Sentiment 0.0
stock
Shanghai Henlius Biotech
Established in-house clinical and regulatory teams in US, Europe, Japan, and Australia to independently operate trials.
Importance 30.0 Sentiment 0.0
priv
Iconiq Capital
Surveyed Asia-Pacific biotech professionals, finding talent shortages nearly three times more likely than global peers.
Importance 20.0 Sentiment 0.0
per
Song Yao
General manager of Iconiq Capital's China business, commented on China's acute recruitment pressure.
Importance 20.0 Sentiment 0.0
per
Richard Pazdur
Former US FDA drug evaluation chief, commented on the need for multi-regional trials.
Importance 20.0 Sentiment 0.0
govactor
Japan — Pharmaceuticals and Medical Devices Agency
Japan's regulatory agency stated most new drugs require Japanese patient data, not solely Chinese studies.
Importance 20.0 Sentiment 0.0
cnt
Japan
More mature pharmaceutical sector; its regulator requires local clinical data, affecting Chinese drugmakers' strategies.
Importance 10.0 Sentiment 0.0
cnt
India
Benefited from outsourcing industry, contrasting with China's acute talent shortage.
Importance 10.0 Sentiment 0.0
priv
Pharmcube
Provided data on licensing deal boom in greater China region.
Importance 10.0 Sentiment 0.0
per
Catherine Gregor
Chief clinical trial officer at Florence Healthcare, stated China faces bottlenecks in global commercialization without internationally trained talent.
Importance 10.0 Sentiment 0.0
+ 5 more entities View on Dashboard
Relationships
China strategic rivals ↔ United States China views the United States as a strategic rival, characterized by ongoing trade disputes, technological competition,
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.